Loading...
•
Sep 30, 2020
Edwards Lifesciences Q3 2020 Earnings Report
Edwards Lifesciences reported better-than-expected results, driven by strong TAVR sales and progress in TMTT clinical trials.
Key Takeaways
Edwards Lifesciences reported a 4% increase in sales to $1.1 billion for the third quarter of 2020. Diluted earnings per share were $0.52, and adjusted earnings per share grew 9% to $0.51. The company is raising the bottom end of full-year 2020 adjusted earnings per share guidance to $1.85 to $1.95.
Sales of $1.1 billion grew 4%; similar underlying growth expected in the fourth quarter
TAVR global sales grew 6%
EPS was $0.52; adjusted EPS grew 9% to $0.51
2020 adjusted EPS guidance increased to $1.85 to $1.95 from $1.75 to $1.95
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
The company anticipates year-over-year underlying sales growth similar to the third quarter. The company is raising the bottom end of full-year 2020 adjusted earnings per share guidance to $1.85 to $1.95, versus previous guidance of $1.75 to $1.95. Looking ahead to 2021, the company anticipates a return to double-digit TAVR growth and aspires to double 2020 TMTT sales.
Positive Outlook
- Year-over-year underlying sales growth similar to the third quarter in Q4 2020
- Raising the bottom end of full-year 2020 adjusted earnings per share guidance to $1.85 to $1.95
- Anticipates a return to double-digit TAVR growth in 2021
- Aspiration to double 2020 TMTT sales
- Optimistic about continuing to deliver innovations to patients around the world
Challenges Ahead
- Ongoing COVID pandemic challenges
- Negative impact from foreign currency fluctuations
- Incremental costs associated with responding to COVID
- Potential delay in initial pivotal clinical trial results by a couple of quarters
- Impact of delayed elective procedures
Revenue & Expenses
Visualization of income flow from segment revenue to net income